Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
- First Posted Date
- 2016-06-17
- Last Posted Date
- 2019-10-15
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 35
- Registration Number
- NCT02804750
Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors
- First Posted Date
- 2016-05-05
- Last Posted Date
- 2022-12-06
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 85
- Registration Number
- NCT02762981
- Locations
- 🇺🇸
014, San Francisco, California, United States
🇺🇸038, Scottsdale, Arizona, United States
🇺🇸001, Chicago, Illinois, United States
Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome
- Conditions
- Cushing's Syndrome
- First Posted Date
- 2016-01-26
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 24
- Registration Number
- NCT02663609
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
- Conditions
- SarcomaProstate CancerBreast CancerOvarian Epithelial Cancer RecurrentNon-small Cell Lung CancerCarcinoma, Transitional CellProstatic Neoplasms
- Interventions
- First Posted Date
- 2013-12-18
- Last Posted Date
- 2018-01-17
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 37
- Registration Number
- NCT02014337
- Locations
- 🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸Rita Nanda, MD, Chicago, Illinois, United States
🇺🇸Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
Mifepristone in Children With Refractory Cushing's Disease
- First Posted Date
- 2013-08-19
- Last Posted Date
- 2014-08-04
- Lead Sponsor
- Corcept Therapeutics
- Registration Number
- NCT01925092
- Locations
- 🇺🇸
National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States
Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
- First Posted Date
- 2011-06-13
- Last Posted Date
- 2014-03-18
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 4
- Registration Number
- NCT01371565
- Locations
- 🇺🇸
The Center for Diabetes and Endocrine Care, Hollywood, Florida, United States
🇺🇸Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸University of Michigan Medical Center, Ann Arbor, Michigan, United States
An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2014-04-02
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT00936741
- Locations
- 🇺🇸
Cleveland Clinic Foundation; Dept of Endocrinology, Diabetes & Metabolism, Cleveland, Ohio, United States
🇺🇸The Center for Diabetes and Endocrine Care, Hollywood, Florida, United States
🇺🇸AMCR Institute Inc., Escondido, California, United States
A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia
- Conditions
- Cushing's Syndrome
- Interventions
- Drug: Cushing's syndrome confirmation
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2014-06-20
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 2
- Registration Number
- NCT00796783
- Locations
- 🇺🇸
AMCR Institute Inc., Escondido, California, United States
🇺🇸The Center for Diabetes and Endocrine Care, Hollywood, Florida, United States
🇺🇸Diabetes and Glandular Disease Research, San Antonio, Texas, United States
A Phase I Study to Determine the Effect of Mifepristone on the Pharmacokinetics of Fluvastatin in Healthy Volunteers
- First Posted Date
- 2008-09-16
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT00752843
- Locations
- 🇺🇸
MDS Pharma, Tempe, Arizona, United States
A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers
- Conditions
- Healthy
- Interventions
- Drug: Risperidone-matched placeboDrug: Mifepristone-matched placebo
- First Posted Date
- 2008-06-16
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 76
- Registration Number
- NCT00698022
- Locations
- 🇮🇳
Dhirubhai Ambani Life Sciences Centre, Mumbai, India